Last reviewed · How we verify
VIB1116
At a glance
| Generic name | VIB1116 |
|---|---|
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome (PHASE2)
- A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VIB1116 CI brief — competitive landscape report
- VIB1116 updates RSS · CI watch RSS
- Amgen portfolio CI